Zhejiang Huahai Pharma plans to float a $152 million bond offering to build a biopharma facility in Hangzhou, the capital of Zhejiang province. The company will devote almost 70% of the proceeds for the construction of the new facility and the remainder to three smaller projects. Known mainly as an API maker, particularly for “pril” generics, Huahai has been expanding into finished drugs
